SOPH (SOPHiA GENETICS S.A.) צמיחה צפויה ברווח נקי למניה השנה

Current year-over-year EPS dynamics for SOPHiA GENETICS SA (SOPH) are based on the Stability SaaS model, which guarantees recurring payments and high margins. The 18.40 mark reflects the latest data, while business resilience is supported by the low dependence of cancer diagnostics on GDP. Proprietary AI algorithms and significant customer switching costs provide a moat against competitors.

The investment attractiveness of SOPHiA GENETICS SA (SOPH) depends on the business's ability to scale revenues amid strict medical data regulations. By analyzing the annual percentage growth of net income per share, investors assess the real capitalization trend stripped of volatility, which helps identify risks of laboratory IT budget cuts and confirms the sustainability of the fundamental growth in asset value.